Yates, Tom A;    Grint, Daniel J;      (2025)    Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes.                   The Lancet Microbe      , Article 101117.  10.1016/j.lanmic.2025.101117 <https://doi.org/10.1016/j.lanmic.2025.101117>.    (In press).    Green open access